Pipeline

Advanced medicines that demonstrate both strong clinical performance and benefits to patients.

Pipeline

~90

compounds, devices or indications in development individually or under collaboration or license agreement

Close-up of a scientist wearing safety goggles and purple gloves inspecting a clear petri dish

investment

$13.8

R&D investment in 2025

Commitment

~60

programs are in mid and late-stage development

Development

programs granted a designation by at least one major regulatory authority to expedite delivery or review in 2025

Innovative medicines for the future

Since our beginnings, AbbVie has been at the top of the global pharmaceutical industry innovation rankings. In 2020, $5.8 billion was invested in research and development. Our therapeutic pipeline is promising: in the next few years, we will produce innovations in the areas of immunology, virology, neurology and oncology.

You can find an overview of our pipeline here:

AbbVie pipeline (abbvie.com)

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

Who We Are

Strong in Switzerland

Science

Areas of Focus

Patients

Patient Commitment

Join Us

Why AbbVie?

Sustainability

Philanthropy

Pipeline

Innovative medicines for the future